Press release
Immuno-Oncology Market Growth Driven by Rising Cancer Cases and Advanced Therapies
✅ Immuno-Oncology Market: Transforming Cancer Treatment with Immune-Based TherapiesThe Immuno-Oncology Market has emerged as a revolutionary force in the global fight against cancer. Unlike traditional cancer treatments, immuno-oncology focuses on enhancing the body's immune response to target and destroy cancer cells. The market is experiencing robust growth due to rising cancer prevalence, increasing acceptance of immunotherapies, and ongoing clinical research. In 2025, the global immuno-oncology market is projected to be valued at US$ 54.6 Billion and is expected to reach US$ 143.2 Billion by 2032, growing at a CAGR of 14.6% during the forecast period.
Checkpoint inhibitors dominate the market owing to their proven efficacy in treating various cancers like melanoma, lung, and renal cancer. North America holds the leading position in the global market, driven by high healthcare expenditure, early adoption of innovative therapies, and strong R&D infrastructure. Meanwhile, the Asia Pacific region is expected to witness the fastest growth due to increasing cancer rates and rising healthcare investments in countries like China and India.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/11329
✅ Key Highlights from the Report
➤ The market is projected to grow from US$ 54.6 Bn in 2025 to US$ 143.2 Bn by 2032.
➤ Checkpoint inhibitors segment accounted for the largest revenue share in 2024.
➤ North America led the global immuno-oncology market due to robust clinical infrastructure.
➤ Melanoma and lung cancer are among the top therapeutic areas targeted by immuno-oncology drugs.
➤ Biopharmaceutical companies are expanding pipelines with combination therapies.
➤ Asia Pacific is forecast to grow at the fastest CAGR during the forecast period.
✅ Frequently Searched Question
What is immuno-oncology and how does it work?
Immuno-oncology (I-O) is a rapidly evolving field of cancer treatment that utilizes the body's immune system to recognize and destroy cancer cells. Unlike traditional treatments like chemotherapy and radiation, which directly target and kill cancer cells, I-O therapies stimulate the body's natural defenses to detect and eliminate cancerous cells more effectively. The most prominent immuno-oncology therapies include checkpoint inhibitors, cancer vaccines, adoptive cell transfer (ACT), and monoclonal antibodies.
Checkpoint inhibitors, for example, block proteins such as PD-1 or CTLA-4 that prevent T-cells from attacking cancer. Once these pathways are blocked, the immune system can better identify and destroy cancerous cells. Other approaches like CAR T-cell therapy involve genetically modifying a patient's own immune cells to better combat tumors. Immuno-oncology has significantly improved survival rates in some cancers and offers a more targeted, long-lasting effect, with fewer side effects compared to traditional treatments.
✅ Market Segmentation
The immuno-oncology market can be segmented by product type, including checkpoint inhibitors, cytokines, cancer vaccines, monoclonal antibodies, and adoptive cell therapies. Among these, checkpoint inhibitors dominate the market, credited to their proven efficacy in various cancers. Cancer vaccines and ACT are showing significant promise as emerging therapies and are expected to gain traction over the coming years as more products gain FDA approval.
Based on end-user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Hospitals hold the largest share due to the availability of advanced medical infrastructure and access to immuno-oncology therapies. Research centers are instrumental in driving clinical advancements, while specialty clinics are becoming increasingly important for outpatient treatments and follow-up care.
✅ Regional Insights
North America continues to lead the immuno-oncology market due to its advanced healthcare infrastructure, government funding for cancer research, and a strong presence of key industry players. The U.S. alone accounts for the majority share, driven by high awareness and availability of cutting-edge treatments.
Asia Pacific is emerging as a lucrative region, particularly in China, Japan, and India. Growing cancer incidences, coupled with government initiatives to enhance healthcare services and investment in biotechnology, are accelerating market growth in this region.
✅ Market Dynamics
Market Drivers
The primary driver of the immuno-oncology market is the increasing global cancer burden, which necessitates advanced treatment solutions. Additionally, favorable regulatory approvals, ongoing clinical trials, and increased investment in R&D by biotech and pharmaceutical firms are stimulating growth. Rising public awareness and willingness to opt for advanced treatments also contribute to market expansion.
Market Restraints
Despite its potential, the market faces challenges such as the high cost of immuno-oncology therapies, which limits access for patients in low- and middle-income countries. Furthermore, complexities in clinical trial designs and regulatory barriers can delay drug development and market entry.
Market Opportunities
There is significant opportunity in the development of combination therapies, which enhance efficacy and reduce resistance to single-drug treatments. Personalized medicine approaches and expansion into rare and difficult-to-treat cancers are also creating new avenues for growth. Emerging economies provide an untapped market for companies willing to invest in outreach and infrastructure.
✅ Reasons to Buy the Report
☑ Gain an in-depth understanding of the global immuno-oncology market dynamics
☑ Access comprehensive segmentation by product, end-user, and region
☑ Identify emerging trends and innovation opportunities in cancer immunotherapy
☑ Understand competitive strategies and recent developments by key players
☑ Receive actionable insights for strategic planning and investment decision-making
✅ Company Insights
✦ Bristol-Myers Squibb
✦ Merck & Co., Inc.
✦ F. Hoffmann-La Roche Ltd.
✦ AstraZeneca
✦ Novartis AG
✦ Pfizer Inc.
✦ Amgen Inc.
✦ Johnson & Johnson
✦ Gilead Sciences, Inc.
✦ Genentech (a subsidiary of Roche)
■ In 2024, Merck's KEYTRUDA (pembrolizumab) received additional FDA approval for early-stage triple-negative breast cancer.
■ Bristol Myers Squibb launched a global clinical trial evaluating the efficacy of Opdivo in combination with chemotherapy in non-small cell lung cancer.
✅ Conclusion
The immuno-oncology market is redefining how cancer is treated, offering hope through precision and durability in patient outcomes. As innovation continues to evolve and new therapies gain approval, the market is poised for sustained growth. While affordability and accessibility remain challenges, expanding R&D pipelines and emerging market investments will shape the next phase of this dynamic industry. Stakeholders, investors, and healthcare providers should remain engaged as immuno-oncology leads the next generation of cancer treatment strategies.
✅About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
Contact Us:
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immuno-Oncology Market Growth Driven by Rising Cancer Cases and Advanced Therapies here
News-ID: 4102103 • Views: …
More Releases from Persistence Market Research

Global Automotive Active Health Monitoring Systems Market Expected to Surge from …
The Automotive Active Health Monitoring Systems Market is poised for significant growth over the forecast period of 2025 to 2032. This market is projected to expand from USD 683.9 million in 2025 to USD 2,338.3 million by 2032, registering a robust CAGR of 19.20%. Automotive active health monitoring systems are designed to track the real-time status of vehicles, enabling predictive maintenance, reducing downtime, and enhancing overall vehicle safety. With growing…

Primary Packaging Labels Market to Reach US$12.2 Bn by 2031 with Steady Growth a …
➤Overview of the Market
The global primary packaging labels market is a crucial segment of the packaging industry, enabling product identification, regulatory compliance, and brand differentiation. Primary labels are applied directly on product packaging, such as bottles, vials, boxes, and pouches, serving both functional and promotional roles. As consumer awareness of product authenticity and safety continues to rise, demand for innovative labeling solutions is expanding. Moreover, stringent regulatory frameworks in industries…

Shelf Stable Packaging Market to Reach US$10.7 Bn by 2031 with Steady Growth at …
➤Overview of the Market
The shelf stable packaging market plays a critical role in extending the shelf life of food and beverages without the need for refrigeration, ensuring product safety, convenience, and affordability. These packaging solutions-spanning cartons, pouches, cans, and plastic containers-are widely used in ready-to-eat meals, dairy alternatives, sauces, soups, and beverages. Growth in the market is closely linked to evolving consumer lifestyles, increasing urbanization, and demand for long-lasting packaged…

Print Label Market to Reach US$68.6 Bn by 2031 with Steady Growth at 4.3% CAGR - …
➤Overview of the Market
The global print label market is poised for substantial expansion, driven by increasing demand across industries such as food & beverages, pharmaceuticals, cosmetics, and logistics. Labels play a crucial role in brand identity, product differentiation, and regulatory compliance. In addition to providing essential information like product ingredients, expiration dates, and barcodes, printed labels serve as key marketing tools that influence consumer purchase decisions. With the rapid rise…
More Releases for Checkpoint
Comparative Effectiveness of TIGIT Antibodies and Other Checkpoint Inhibitors
The comparative effectiveness of TIGIT antibodies and other checkpoint inhibitors is a topic of significant interest in the field of cancer immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to attack tumors. While PD-1 and CTLA-4 inhibitors have shown remarkable success, TIGIT antibodies offer a new approach with potentially complementary mechanisms.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1 receptor on T…
Checkpoint Inhibitors Market Report 2024: Advancing Cancer Treatments
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Checkpoint Inhibitors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $55.64 billion In 2028 At…
Checkpoint Inhibitors Competitive Landscape Report 2023
DelveInsight's, "Checkpoint Inhibitors Competitive Landscape 2023" report provides comprehensive insights about 180+ Checkpoint Inhibitors Companies and 250+ drugs in the Checkpoint inhibitors Competitive landscape. It covers the Checkpoint Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report
• DelveInsight's Checkpoint Inhibitors report depicts a robust space with 180+ Glioma…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…